Spots Global Cancer Trial Database for irinotecan hydrochloride
Every month we try and update this database with for irinotecan hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00639769 | Head and Neck C... | cisplatin irinotecan hydr... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | NCT00492999 | Colorectal Canc... Metastatic Canc... | dexamethasone floxuridine fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors | NCT00004923 | Unspecified Adu... | docetaxel irinotecan hydr... | 18 Years - | Yale University | |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | NCT00134069 | Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | sorafenib tosyl... cetuximab irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00099125 | Brain and Centr... | irinotecan hydr... temozolomide adjuvant therap... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma | NCT00002988 | Brain and Centr... | carmustine irinotecan hydr... | 18 Years - | Duke University | |
| S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer | NCT00109850 | Esophageal Canc... | cetuximab cisplatin irinotecan hydr... radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00080951 | Colorectal Canc... | fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | NCT00004870 | Colorectal Canc... | oblimersen sodi... irinotecan hydr... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer | NCT00104793 | Lung Cancer | carboplatin irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer | NCT00005638 | Esophageal Canc... Gastric Cancer | cisplatin irinotecan hydr... radiation thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer | NCT00005076 | Colorectal Canc... | cetuximab irinotecan hydr... | 18 Years - | University of Alabama at Birmingham | |
| Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer | NCT00040807 | Head and Neck C... | docetaxel irinotecan hydr... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy in Treating Patients With Colorectal Cancer | NCT00006103 | Colorectal Canc... | fluorouracil irinotecan hydr... leucovorin calc... | - | Alliance for Clinical Trials in Oncology | |
| Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | NCT00005951 | Brain and Centr... | irinotecan hydr... temozolomide | 18 Years - | Duke University | |
| Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00182806 | Lung Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - | Roswell Park Cancer Institute | |
| Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | NCT02345460 | Pancreatic Aden... Poorly Differen... Resectable Panc... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Undifferentiate... | Irinotecan Hydr... Oxaliplatin Leucovorin Calc... Fluorouracil Laboratory Biom... | 18 Years - 75 Years | Case Comprehensive Cancer Center | |
| Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer | NCT00008060 | Colorectal Canc... | FOLFIRI regimen FOLFOX regimen fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan in Treating Patients With Colorectal Cancer | NCT00003843 | Colorectal Canc... | irinotecan hydr... mutation analys... polymorphism an... | 18 Years - | California Cancer Consortium | |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | NCT00042939 | Pancreatic Canc... | cetuximab docetaxel irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors | NCT00003710 | Unspecified Adu... | irinotecan hydr... mitomycin C | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer | NCT00026273 | Colorectal Canc... | FOLFIRI regimen fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 75 Years | Pfizer | |
| Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors | NCT01141244 | Unspecified Chi... | temsirolimus temozolomide irinotecan hydr... laboratory biom... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer | NCT00062322 | Lung Cancer | cisplatin irinotecan hydr... conventional su... neoadjuvant the... radiation thera... | 18 Years - | Fox Chase Cancer Center | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer | NCT00524186 | Esophageal Canc... Gastric Cancer | fluorouracil irinotecan hydr... leucovorin calc... sunitinib malat... flow cytometry pharmacological... | - 120 Years | Roswell Park Cancer Institute | |
| Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | NCT00655499 | Colorectal Canc... | Panitumumab Irinotecan hydr... Chromogenic in ... Fluorescence in... Gene expression... Laboratory biom... | 18 Years - 80 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer | NCT01320683 | Liver Metastase... Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | oxaliplatin leucovorin calc... fluorouracil bevacizumab yttrium Y 90 DO... laboratory biom... pharmacological... irinotecan hydr... | 18 Years - | City of Hope Medical Center | |
| S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer | NCT00134095 | Gastric Cancer | irinotecan hydr... tegafur-gimerac... adjuvant therap... conventional su... neoadjuvant the... | 20 Years - 75 Years | National Cancer Institute (NCI) | |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | NCT04535401 | Advanced Colore... Advanced Digest... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Dige... Metastatic Gast... Metastatic Gast... Stage III Color... Stage IV Colore... | Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Fluorouracil Irinotecan Hydr... Leucovorin Calc... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | NCT00303992 | Breast Cancer | trastuzumab irinotecan hydr... | - 120 Years | University of California, San Francisco | |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | NCT00134069 | Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | sorafenib tosyl... cetuximab irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | NCT00980460 | PRETEXT I Hepat... PRETEXT II Hepa... PRETEXT III Hep... PRETEXT IV Hepa... | Cisplatin Dexrazoxane Doxorubicin Hyd... Fluorouracil Irinotecan Hydr... Laboratory Biom... Liver Transplan... Temsirolimus Therapeutic Con... Vincristine Sul... | - 21 Years | National Cancer Institute (NCI) | |
| Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | NCT05799443 | Colorectal Canc... | Tislelizumab Irinotecan Hydr... cetuximab SBRT | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer | NCT00006269 | Colorectal Canc... Diarrhea | irinotecan hydr... octreotide acet... | 18 Years - | Novartis | |
| Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer | NCT00075595 | Colorectal Canc... | FOLFIRI regimen fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme. | NCT02433392 | Glioma | CM-BC2 | 18 Years - | Boston Scientific Corporation | |
| Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | NCT00010036 | Brain and Centr... | carboplatin irinotecan hydr... radiation thera... | 18 Years - | NYU Langone Health | |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | NCT01498289 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | NCT04535401 | Advanced Colore... Advanced Digest... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Dige... Metastatic Gast... Metastatic Gast... Stage III Color... Stage IV Colore... | Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Fluorouracil Irinotecan Hydr... Leucovorin Calc... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | NCT00513266 | Colorectal Canc... Metastatic Canc... | bevacizumab cetuximab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin laboratory biom... adjuvant therap... biopsy conventional su... neoadjuvant the... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT02975882 | Childhood Solid... Recurrent Malig... Recurrent Prima... Refractory Mali... Refractory Prim... | Irinotecan Hydr... Laboratory Biom... Pharmacological... Sirolimus Album... Temozolomide | 12 Months - 21 Years | Children's Oncology Group | |
| Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer | NCT00296062 | Colorectal Canc... Unspecified Adu... | bevacizumab capecitabine irinotecan hydr... oxaliplatin | 18 Years - | Case Comprehensive Cancer Center | |
| PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | NCT02049593 | Metastatic Canc... Unspecified Adu... | PARP inhibitor ... temozolomide irinotecan hydr... pharmacological... laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT01473303 | Pancreatic Canc... | ganitumab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin placebo questionnaire a... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | NCT00628810 | Colorectal Canc... | bevacizumab fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 74 Years | Federation Francophone de Cancerologie Digestive | |
| Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | NCT00287976 | Liver Cancer | irinotecan hydr... | - 20 Years | National Cancer Institute (NCI) | |
| Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer | NCT00003427 | Anal Cancer Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | irinotecan hydr... oxaliplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors | NCT00112892 | Unspecified Adu... | selenium irinotecan hydr... | 18 Years - | Roswell Park Cancer Institute | |
| Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | NCT00217711 | Colorectal Canc... | Capecitabine irinotecan hydr... oxaliplatin | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | NCT01814501 | Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IV Colon ... Stage IV Rectal... | panitumumab irinotecan hydr... fluorouracil leucovorin calc... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | NCT02573220 | Stage IVA Color... Stage IVB Color... | Cetuximab Fluorouracil Irinotecan Hydr... Leucovorin Calc... | 18 Years - | University of Chicago | |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases | NCT01939483 | Central Nervous... Male Breast Can... Recurrent Breas... Stage IV Breast... | irinotecan hydr... laboratory biom... | 18 Years - | University of California, Irvine | |
| Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer | NCT00002939 | Unspecified Adu... | irinotecan hydr... paclitaxel | 18 Years - | University of Chicago | |
| S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | NCT03365882 | Colon Adenocarc... ERBB2 Gene Ampl... Rectal Adenocar... Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | Cetuximab Irinotecan Hydr... Laboratory Biom... Pertuzumab Trastuzumab HER-2 testing | 18 Years - | SWOG Cancer Research Network | |
| Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors | NCT00112892 | Unspecified Adu... | selenium irinotecan hydr... | 18 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy | NCT00006095 | Unspecified Chi... | irinotecan hydr... vincristine sul... | 1 Year - 21 Years | Children's Oncology Group | |
| FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | NCT03110510 | Biliary Tract C... | Fluorouracil Irinotecan Hydr... leucovorin calc... | 20 Years - | Samsung Medical Center | |
| Irinotecan in Treating Patients With Advanced Cancer of the Stomach | NCT00003137 | Esophageal Canc... Gastric Cancer | irinotecan hydr... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | NCT00628810 | Colorectal Canc... | bevacizumab fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 74 Years | Federation Francophone de Cancerologie Digestive | |
| Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655) | NCT00023868 | Colorectal Canc... Metastatic Canc... | FOLFIRI regimen cisplatin doxorubicin hyd... fluorouracil irinotecan hydr... leucovorin calc... mitomycin C | 18 Years - 120 Years | American College of Radiology Imaging Network | |
| Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer | NCT00100828 | Head and Neck C... | irinotecan hydr... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | NCT00004922 | Carcinoma of Un... Neuroendocrine ... Neuroendocrine ... | irinotecan hydr... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases | NCT00617539 | Breast Cancer Metastatic Canc... | irinotecan hydr... temozolomide | 18 Years - 120 Years | University of California, San Francisco | |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | NCT00005972 | Lung Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | NCT01643499 | Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex... | oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom... | 18 Years - | University of Chicago | |
| Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer | NCT00020748 | Unspecified Adu... | epirubicin hydr... irinotecan hydr... | 18 Years - | Georgetown University | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer | NCT00003344 | Colorectal Canc... | irinotecan hydr... radiation thera... | 18 Years - 120 Years | Medical University of South Carolina | |
| N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | NCT00093353 | Diarrhea Drug/Agent Toxi... Neuroblastoma | cefixime irinotecan hydr... temozolomide | 1 Year - 30 Years | Children's Hospital Los Angeles | |
| Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | NCT01205022 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | irinotecan hydr... leucovorin calc... fluorouracil bevacizumab yttrium Y 90 DO... laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00469898 | Lung Cancer | Carboplatin irinotecan hydr... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | NCT00010036 | Brain and Centr... | carboplatin irinotecan hydr... radiation thera... | 18 Years - | NYU Langone Health | |
| Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00084604 | Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri... | irinotecan hydr... bevacizumab cisplatin computed tomogr... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00084877 | Unspecified Adu... | triapine irinotecan hydr... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan in Treating Patients With Advanced Solid Tumors | NCT00004051 | Unspecified Adu... | irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | NCT00004870 | Colorectal Canc... | oblimersen sodi... irinotecan hydr... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | NCT01167725 | Colorectal Canc... | bevacizumab cetuximab FOLFIRI regimen FOLFOX regimen capecitabine fluorouracil irinotecan hydr... leucovorin calc... mitomycin C oxaliplatin therapeutic con... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
